Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
April 01 2014 - 4:00PM
Marketwired
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for
Presentation at AACR 2014 Annual Meeting
TUSTIN, CA--(Marketwired - Apr 1, 2014) - Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a
biopharmaceutical company developing first-in-class monoclonal
antibodies focused on the treatment and diagnosis of cancer, today
announced the acceptance of three preclinical abstracts scheduled
for poster presentations at the 105th Annual Meeting of the
American Association for Cancer Research (AACR), to be held April
5-9, 2014 in San Diego, California. Data to be presented include
studies investigating the therapeutic potential of Peregrine's
phosphatidylserine (PS)-targeting antibodies when administered in
combination treatment regimens with irradiation as well as with
approved and developmental cancer immunotherapies.
Abstract Details:
Abstract Number: 639 Presentation Title: Antibody-mediated
blockade of phosphatidylserine combined with radiation improves
survival and tumor eradication in a rat model of non-small cell
lung cancer Presentation Time: Sunday, April 6, 2014, 1:00 PM -
5:00 PM Location: Hall A-E, Poster Section 27 Poster Board Number:
14 Author Block: Olivier Belzile, Zhang Zhang, Xianming Huang,
Debabrata Saha, Rolf A. Brekken. University of Texas Southwestern
Medical Center, Dallas, Texas
Late-Breaking Abstract Number: LB-262 Presentation Title:
Phosphatidylserine-targeting antibody synergizes with anti-PD-1
antibody to inhibit tumor growth in K1735 mouse melanoma model
Presentation Time: Tuesday, April 8, 2014, 1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 41 Author Block: Xianming Huang,
Dan Ye, Rolf Brekken, Yi Yin. UT Southwestern Medical Center,
Dallas, Texas
Abstract Number 4978 Presentation Title: Targeting of
phosphatidylserine by monoclonal antibodies enhances activity of
immune checkpoint inhibitors in tumors Presentation Time:
Wednesday, April 9, 2014, 8:00 AM -12:00 PM Location: Hall A-E,
Poster Section 7 Poster Board: 2 Author Block: Jian Gong, Van
Nguyen, Shen Yin, Rich Archer, Jeff Hutchins, Bruce Freimark.
Peregrine Pharmaceuticals, Inc., Tustin, California
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a pipeline of novel drug
candidates in clinical trials for the treatment and diagnosis of
cancer. The company is developing multiple clinical programs in
cancer with its lead immunotherapy candidate bavituximab while
seeking a partner to further advance its novel brain cancer agent
Cotara®. Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com.
Contact: Christopher Keenan or Jay Carlson Peregrine
Pharmaceuticals (800) 987-8256 info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024